Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Neutral Rating by Piper Sandler

Key Points

• Piper Sandler downgraded Tvardi Therapeutics from an "overweight" to a "neutral" rating, significantly lowering the target price from $78.00 to $4.00, indicating a potential downside of 41.43% from the current price.
• Tvardi Therapeutics' stock has plummeted 83.6%, trading at $6.83, with a twelve-month high of $43.65 and a low of $5.65.
• The company's recent quarterly earnings showed a loss of ($1.00) EPS, missing analyst estimates, and it has a negative return on equity of 565.83%.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) was downgraded by stock analysts at Piper Sandler from an "overweight" rating to a "neutral" rating in a report issued on Monday, MarketBeat.com reports.

Several other equities research analysts have also commented on the stock. Barclays began coverage on shares of Tvardi Therapeutics in a research note on Monday. They set an "overweight" rating and a $61.00 price target on the stock. Weiss Ratings reaffirmed a "sell (e)" rating on shares of Tvardi Therapeutics in a report on Saturday, September 27th. Raymond James Financial started coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They issued an "outperform" rating and a $62.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Tvardi Therapeutics in a research report on Friday, July 11th. They set an "overweight" rating and a $52.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tvardi Therapeutics currently has a consensus rating of "Hold" and an average price target of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD traded down $35.04 during mid-day trading on Monday, reaching $6.56. 4,494,120 shares of the company were exchanged, compared to its average volume of 58,488. Tvardi Therapeutics has a 1 year low of $5.65 and a 1 year high of $43.65. The company has a 50-day moving average price of $32.02.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new stake in Tvardi Therapeutics in the second quarter worth approximately $2,617,000. Marshall Wace LLP purchased a new stake in Tvardi Therapeutics during the second quarter valued at about $583,000. Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at $399,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at $92,000. Finally, Headlands Technologies LLC bought a new position in Tvardi Therapeutics in the 2nd quarter worth about $80,000. 44.66% of the stock is currently owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.